Compound A PDE4 Inhibitor for Idiopathic Pulmonary Fibrosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for idiopathic pulmonary fibrosis (IPF), such as steroids and immunosuppressants, are ineffective, and anti-fibrosis agents like pirfenidone have limited efficacy and adverse effects, necessitating a more effective therapeutic option.
Innovation Solution
A pharmaceutical composition comprising a phosphodiesterase 4 (PDE4) inhibitor, specifically 5-((2R,4aR,10bR)-9-Ethoxy-2-hydroxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl)-1-methyl-1H-pyridin-2-one (Compound A) or its pharmaceutically acceptable salts, is used to treat IPF, potentially combined with other active pharmaceutical ingredients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If steroids and immunosuppressant agents are used for IPF treatment, then anti-inflammatory effects are achieved, but they are ineffective for IPF specifically
Solution Approach 1:
The patent transitions from using conventional anti-inflammatory drugs (steroids, immunosuppressants) to a PDE4 inhibitor with specific pharmacological properties tailored for fibrotic diseases. This involves changing the drug class and mechanism of action to target the specific pathophysiology of IPF, including inhibition of fibroblast activation and TGF-β signaling pathways.
2Reliability
If pirfenidone is used as an anti-fibrosis agent, then fibrosis progression is slowed, but adverse effects in digestive organs and photo toxicity occur
Solution Approach 1:
The patent changes the pharmacological parameters by selecting a PDE4 inhibitor instead of pirfenidone, aiming to achieve similar anti-fibrotic effects through a different mechanism that may have a more favorable side effect profile. The PDE4 inhibition targets cAMP signaling pathways involved in fibrosis while potentially reducing gastrointestinal and photosensitivity adverse effects.
3Reliability
If current anti-fibrosis treatments are used, then some fibrosis progression is halted, but the efficacy is limited
Solution Approach 1:
The patent combines the anti-fibrotic effects of PDE4 inhibition with potential synergistic mechanisms targeting multiple pathways involved in IPF pathogenesis. This includes inhibition of TGF-β signaling, fibroblast activation, and extracellular matrix production, aiming to achieve greater than additive therapeutic effects and improve survival outcomes.
Data Source
Figure 1(A)
Figure 1(B)
Figure 2(A)~2(D)
AI summary
The present invention is directed to the treatment of idiopathic pulmonary fibrosis with (a) a phosphodiesterase (4) inhibitor (b) a phosphodiesterase (4) inhibitor and a second active pharmaceutical ingredient.